MAIA Biotechnology, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS Issuance of Options From July 1 to August 11, 2025, the Company issued 416,806 options at a weighted exercise price of $1.91 to consultants. At-The-Market Offering with H.C. Wainwright Since July 1, 2025, the Company has sold 1,174,740 shares of its Common Stock through Wainwright under the ATM Agreement at an average price of approximately $1.92 per share, resulting in aggregate gross proceeds of approximately $2,257,039, for which it paid Wainwright approximately $67,711 in commissions, resulting in net proceeds to the Company of approximately $2,189,328. The Company anticipates that the at-the-market offering will continue throughout the next reporting period.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2025

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

9. SUBSEQUENT EVENTS

Issuance of Options

From July 1 to August 11, 2025, the Company issued 416,806 options at a weighted exercise price of $1.91 to consultants.

At-The-Market Offering with H.C. Wainwright

Since July 1, 2025, the Company has sold 1,174,740 shares of its Common Stock through Wainwright under the ATM Agreement at an average price of approximately $1.92 per share, resulting in aggregate gross proceeds of approximately $2,257,039, for which it paid Wainwright approximately $67,711 in commissions, resulting in net proceeds to the Company of approximately $2,189,328. The Company anticipates that the at-the-market offering will continue throughout the next reporting period.